No Data
No Data
Huaxin Securities: Both the supply and demand sides of blood products continue to improve, and the scale effect of leading companies gradually emerges.
According to the research report released by Huaxin Securities, with the support and attention of domestic policies, the planning of plasma stations such as "14th Five-Year Plan" is gradually landing, and the construction of plasma stations is accelerating. The scale of plasma collection in China will continue to increase. In 2023, the plasma collection volume will exceed 12,079 tons, an increase of more than 18.6% compared to 2022. Blood products are essential medicines and the entire industry is licensed businesses, which determines their natural high policy barrier characteristics. Plasma collection scale, plasma comprehensive utilization rate, and plasma profit-making ability are the core factors. Plasma collection scale directly determines the size of enterprises, and the number of existing varieties and research products are used to determine the plasma comprehensive utilization rate and plasma profit-making ability.
Weiguang Biological Products Gets Nod for Human Prothrombin Complex
Shenzhen Weiguang Biological Products (SHE:002880) received a drug registration certificate from China's National Medical Products Administration for its human prothrombin complex, according to a Frid
Express News | Weiguang Biotech: Received the “Drug Registration Certificate” for human prothrombin complex
Weiguang Biology (002880.SZ): The main business is blood products. It is a bioactive preparation prepared from healthy human plasma using biological processes or separation and purification technology
Gelonghui, May 24 | Weiguang Biology (002880.SZ) said on the investor interactive platform that the company's main business is blood products, which are bioactive preparations prepared using biological processes or separation and purification techniques using healthy human plasma as raw materials. Weiguang Life Science Park focuses on synthetic biology, brain science, etc., to build a core technology platform for genes, macromolecules, and cells, and is committed to building a biomedical specialty park characterized by innovation incubation and transformation of results.
Weiguang Biotech (002880): Performance is in line with expectations, fiber revenue is growing rapidly
Incident: The company released the 2023 report & 2024 quarterly report. In 2023, it achieved revenue of 1.05 billion yuan, +57% year-on-year, and realized net profit of 220 million yuan to mother, +86.1% year-on-year, after deducting net profit of 210 million yuan other than the mother
Weiguang Biotech (002880.SZ): Net profit of 468.319 million yuan in the first quarter increased 2.40% year-on-year
Gelonghui, April 25 | Weiguang Biotech (002880.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 226 million yuan, up 8.53% year on year; net profit attributable to shareholders of listed companies was 468.319 million yuan, up 2.40% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 455.227 million yuan, up 1.23% year on year; basic earnings per share were 0.2065 yuan.
No Data